anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tissue and organ transplantation success is chiefly dependent on the harvest and preservation techniques employed. Yield and quality enhancements are needed, because qualified patient demand far outpaces donors and ultimately, tissues and organs stored and transported so as to render them in acceptable condition for surgery. In the case of corneal transplants, tissue supplies help 1 out of 70 patients in need despite being among the most successful such procedures today. Transplant success has improved overall with enhanced storage and transport methods that have allowed for greater time and distances to reach patients in need, whether corneas, kidneys, hearts, lungs, livers or other tissues, limbs or cellular materials. While corneal tissues specifically benefit from oxygenation via direct air contact and normal tears in a healthy individual, once donated, the lack of corneal vascularization can uniquely accelerate the depletion of oxygen that occurs upon harvesting of all transplant materials. Directly infusing oxygen has had little impact, given partial pressure requirements, volatility and reactivity to many compounds, including self-affinity or agglomeration and bubbling. However, the hemocyanin, such as that of the horseshoe crab (Limulus polyphemus), can deliver oxygen directly to transplant tissues, while free radical scavenging by pristine fullerenes can help maintain cellular integrity. Horseshoe crabs have successfully evolved by developing two immunological mechanisms, amoebocytes and less characterized antiviral and gram-positive bactericidal properties ascribed to other hemolymph constituents. The amoebocytes have a specific, ultrasensitive affinity to gram-negative bacteria and fungi; they engulf and consume these microbes in an enzymatic coagulation process. However, hemocyanin is extracellular and non-toxic to mammalian tissue, notwithstanding its microbiocidal properties. As such, the viral-scale peptides appear to intracellularly invade the pathogens and disrupt replication without conferring a caustic or toxic effect on non-pathogenic tissue. Hence, hemocyanin appears to be non-immunogenic and thus applicable as a carrier molecule for some human therapeutics (e.g., hemocyanin from Keyhole Limpet snails). The present invention relates in the initial embodiment to the use of horseshoe crab hemocyanin and functionalized carbon nanostructures, halogenated fullerenes, pristine fullerenes and fullerene derivatives as an antimicrobial and antioxidant enrichment composition that is added to tissue storage and preservation media as a potent, broad-spectrum antimicrobial and tissue preservation composition for safe and effective storage and transport. Notably, methods for horseshoe crab aquaculture husbandry have been developed to achieve sustainable hemocyanin supplies for hemolymph harvest and biomedical applications. With regard to unique needs and benefits for the transplantation of corneal tissue, the aim of this patent is development of an antioxidant and broad-spectrum microbicidal that is benign to endothelial and endothelium cells to preserve and maximize the viability of a pathogen-free specimen.
FIELD: medicine, pharmaceutics. SUBSTANCE: tablet of antimicrobial action contains the derivative of isonicotinic acid hydrazide as flurenizide, starch and calcium stearate. It additionally contains methylcellulose and TWIN-80. Moreover, the tablet is covered with any pharmaceutically acceptable material. The tabletted preparation has the wide spectrum of antimicrobial action, provides high therapeutical efficiency. It is, also, characterized by the absence of any side action and toxicoallergic reactions. The invention could be applied for treating diseases as a result of tubercular and chlamydial infections. EFFECT: higher efficiency of therapy. 2 cl, 2 ex, 2 tbl
The use of meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week, double-blind, parallel-arm, active-controlled trials. 

Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam dosing began at 0.125 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum), and naproxen dosing began at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.

The efficacy analysis used the ACR Pediatric 30 responder definition, a composite of parent and investigator assessments, counts of active joints and joints with limited range of motion, and erythrocyte sedimentation rate. The proportion of responders were similar in all three groups in both studies, and no difference was observed between the meloxicam dose groups.
HUMAN LEUKOYTE ELASTASE INHIBITORS AND   METHODS OF PRODUCING AND USING SAME                    ABSTRACT OF THE DISCLOSURE Compounds selected from the group consisting of a compound of the formula                            (I) and a compound of the formula                              (II) wherein x is 1 or 2, Y is carbobenzoxy or benzoyl, and XR is   have use as elastase enzyme inhibitors.  Particularly potent are the L-proline diastereomers.     Elastase Enzyme inhibitory compositions comprise a carrier and an elastase enzyme inhibiting amount of the compounds of the invention.     A method of selectively inhibiting the enzyme elastase in an animal  or  a  human  in  need  of  such  treatment  comprises administering  to  the  animal  or  human  an  enzyme  elastase inhibiting amount of one of the compounds of the invention or a composition thereof.      A  method  of  reducing  corneal  scarring  or  fibroblast proliferation comprises applying to an area of a subject's eye afflicted  with  the  condition  a  corneal  scar-  fibroblast proliferation-reducing amount  of  a  free  or polymer-bound HLE inhibitory  agent  under  conditions and  for  a period  of  time effective to attain the desired effect.   A method of reducing neovascularization of corneal scar tissue comprises applying to an area  of  a  subject's  eye  afflicted  with  the  condition  a neovascularization-inhibitory amount of a free or polymer-bound HLE inhibitory agent under conditions and for a period of time effective to attain the desired effect.
Rabeprazole 20mg twice daily, bismuth potassium citrate 220mg twice daily, Amoxycillin 1g twice daily, clarithromycin 500mg twice daily. The duration is 14 days.
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers.; Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A ("PE") with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.
The invention provides a synthesis method of a novel 9-O-aryl substituted berberine derivative 5 and a 9-O-phenyl bridged berberine dimer 7. Taking berberine 1 as a raw material, removing methyl on the 9 th position to obtain berberberrubine 2, protonating the berberrubine 2 and reducing to obtain tetrahydroberberberrubine 3. 3 and iodo-aromatic hydrocarbon under the protection of nitrogen to carry out C-O cross coupling reaction to obtain a product 4, and then oxidizing to obtain the target 9-O-aryl substituted berberine derivative 5. The berberine dimer 7 is obtained by coupling and oxidizing 3 and 4 degrees. The berberine derivative has the advantages of good lipid solubility, simple preparation method, high yield and the like. In vitro experiments show that the berberine derivatives have better inhibitory action on staphylococcus aureus, so the berberine derivatives have potential application value in the field of antibacterial drugs.
The present invention relates to a cleansing foam formed of fiber cotton or composite yarn containing a cleansing composition. The cleansing foam includes: a double-ply cleansing pad composed of a sealing part sealed on the outer periphery by thermocompression bonding so that a pocket part having a space part is formed inside the first and second cleansing pads formed of the double-ply cleansing pad; a capsule-shaped cleaning capsule filled with a cleansing filler filled with a cleansing composition to clean foreign substances or cosmetics inside the double-ply cleansing pad and discharged by a user; and a plastic packaging pack in which the double-ply cleansing pad and the cleaning capsule are stacked with one side overlapping to form an opening for disposable use. The cleaning capsule is filled with a cleansing filler containing a cleansing composition, and the disposable cleansing foam can be used multiple times. The moisture of the disposable cleansing foam used previously does not dry out and can be used repeatedly and conveniently multiple times. Even with little physical force, the user can conveniently use the cleansing foam repeatedly as the cleansing filler is withdrawn. It is possible to prevent the face from being damaged after using the cleansing filler. Depending on the user, the cleansing foam can be easily used anywhere and the moisture filler can be easily filled.
The invention provides an externally applied antithyroid gel. The externally applied antithyroid gel comprises a medicament, a macromolecular substrate material, a solvent, a cosolvent, a humectant and a preservative, and selectively contains any of an antioxidant, a neutralizer and a penetration enhancer. Defects of the traditional curative medicament are overcome by the externally applied antithyroid gel. When smeared on a neck lesion site, the antithyroid gel has high absorption effect, obvious treatment effect and no obvious side effect for the whole body, and is suitable for mass production. Particularly, no trace or residue is left on the smeared part after the antithyroid gel is smeared or absorbed. When the antithyroid gel is used for treating hyperthyroidism, the repeated incidence and the relapse rate are low, the treatment effect on hyperthyroidism is improved, and pains of patients are alleviated.
BACK GROUND: 7-Methoxycoumarin (7-MC) is well recognized for its anti-inflammatory and anti-nociceptive actions. Its capacity to lessen neuropathic pain hasn't been documented yet. Hence the impact of 7-MC on vincristine-induced peripheral neuropathic pain in rodents was investigated. The investigation also looked at the impact of 7-MC in reducing neuropathic pain via voltage-gated calcium channels and phospholipase enzyme inhibition using pertinent in vitro and in silico methods.
METHODS AND RESULTS: Vincristine (0.1 mg/kg, i.p., daily) was administered continuously for 7 days to induce peripheral neuropathic pain in mice, with cold allodynia and thermal hyperalgesia and evaluated on the 8th day using the acetone bubble test and hot water tail immersion test. In order to derive the mechanistic approach for ameliorating neuropathic pain, the role of 7-MC in the inhibition of the phospholipase enzyme, gene expression studies on voltage-gated calcium channels using mouse BV2 microglial cells and in silico studies for its calcium channel binding affinity were also performed. The test compounds reduced vincristine-induced cold allodynia and thermal hyperalgesia in mice in a dose-dependent experiments. In vitro studies on phospholipase inhibition by 7-MC showed an IC50 of 27.08 µg/ml and down-regulated the gene expression of calcium channels in the BV2 microglial cell line. In silico docking scores for 7-MCwere higher than the standard drug gabapentin.
CONCLUSION: The compound 7-MC has shown promise in alleviating vincristine-induced peripheral neuropathicin mice. Studies conducted in parallel, both in silico and in vitro have demonstrated that 7-MC effectively reduces neuropathic pain. This pain reduction is achieved through two mechanisms: inhibiting the phospholipase enzyme and blocking voltage-gated calcium channels.
In this study the investigators will examine whether the alterations of doppler indices in the uterine, ovarian and spiral arteries can help to explain tubal or unexplained infertility as a standard screening method. Patients in unexplained-tubal infertility groups were treated in our IVF clinic. Patients will be invited to the hospital according to the criteria of the study. Fertile patients will be selected according to the criteria for patients who have come for the annual smear control. The study hypothesis is that the resistance in ovarian, uterine and spiral artery doppler will be higher in cases with tubal and unexplained infertility as opposed to low resistance in fertile women.Ovarian, uterine and spiral artery pulsatility index (PI = (peak systolic velocity - end diastolic velocity) / time averaged velocity and resistance index ( RI= (peak systolic velocity - end diastolic velocity) / peak systolic velocity ) will measure with doppler ultrasonography in the mid-luteal phase ( 21th day). Measured values are to be compared.
The invention relates to an antibody-small molecule drug conjugate capable of inhibiting tumor growth, and a preparation method and application thereof. The invention provides an anti-Her2 antibody-small molecule drug conjugate (antibody-drug conjugate or ADC). The traditional monoclonal antibody is subjected to conjugate modification, and an unresectable chemical linker with higher stability than the traditional chemical linker is selected before systemic circulation. The conjugate has higher targeting property than the traditional chemotherapy and radioactive therapy. Compared with the traditional anti-Her2 monoclonal antibody, the conjugate has better drug effect healing windows. The conjugate has higher stability in systemic circulation, and lowers the toxicity of the drug before entering the tumor cells. The invention provides a preparation method and application of the antibody-small molecule drug conjugate.
Each year 17 million people suffer stroke worldwide. According to the World Stroke Organization, stroke has become the second cause of death and disability worldwide. In the United States, every year, more than 795,000 people have a stroke. Given the large-scale challenges of curing stroke, prevention and treatments for stroke are much needed. Ischemic stroke is treatable in many patients if they have early access to viable treatments.

This trial is a prospective, multicenter, open-label, single-arm trial designed to assess the potential treatment benefits of using the Imperative Care 0.088" Catheters in conjunction with the other devices in the Zoom Reperfusion System to restore blood flow in patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease. The Zoom Reperfusion System includes the Imperative Care 0.088" Catheters, the Zoom Reperfusion Catheters (0.035" to 0.071" Catheters), Zoom Aspiration Tubing, and Zoom Aspiration Pump. The trial will assess reperfusion success using the mTICI scores in the absence of any rescue therapy, reperfusion time, first-pass success, and functional independence including a quality-of-life assessment.
Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], B/Victoria \[B/Malaysia/2506/2004\], and B/Yamagata \[B/Florida/4/2006\]).
All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
PURPOSE OF REVIEW: In the evolving landscape of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) management, liquid biopsy offers unprecedented opportunities for guiding clinical decisions. Here, we review the most recent findings on liquid biopsy applications in HER2-positive BC and its potential role in addressing challenges specific to this BC subtype.
RECENT FINDINGS: Recent studies have highlighted the significance of liquid biopsy analytes, primarily circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), in stratifying patients' prognosis, predicting treatment response, and monitoring tumor evolution in both early and advanced stages of BC. Liquid biopsy holds promise in studying minimal residual disease to detect and potentially treat disease recurrence before it manifests clinically. Additionally, liquid biopsy may have significant implication in the management of brain metastasis, a major challenge in HER2-positive BC, and could redefine parameters for determining HER2 positivity. Combining ctDNA and CTCs is crucial for a comprehensive understanding of HER2-positive tumors, as they provide complementary insights.
SUMMARY: Research efforts are needed to address analytical challenges, validate, and broaden the application of liquid biopsy in HER2-positive BC. This effort will ultimately facilitate its integration into clinical practice, optimizing the care of patients with HER2-positive tumors.
Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 \> 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI \> 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
A number of complications are associated with COVID-19 due to reduced immunity. Of these, opportunistic infections are of great significance because of their atypical presentation and low detection rates. Co-infection of various parts of the gastrointestinal system with cytomegalovirus (CMV) is a common occurrence in COVID- 19 patients. Dysphagia and odynophagia are the main complaints of oesophagitis caused by CMV. Colitis due to CMV presents with melena, diarrhoea, or constipation. However, gastritis due to the same agent can be asymptomatic or associated with atypical symptoms like fever and epigastric pain. Cytomegalovirus gastritis can be fatal if not detected early. Hence, continued monitoring of routine baseline investigations is imperative until the complete resolution of COVID-19, as prompt diagnosis improves the outcomes.
Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
Anorectal malformations (ARM) encompass a spectrum of rare congenital defects of the rectum and anus, requiring specialized reconstructive surgery. To improve epidemiological and clinical research in rare diseases such as ARM, collaborative efforts and patient registries are key. This retrospective study pools clinical data over a 30-year period from two ARM patient registries (The Royal Children's Hospital (RCH) in Melbourne, Australia, and the ARM-Network Consortium in Europe). It aims to draw comparisons on demographics, management, and outcomes between ARM patients in Australia and Europe. A total of 2947 ARM patients were included in the analyses. The RCH cohort had more complex ARM types (including rectal atresia and recto-vaginal fistula) and more associated anomalies, specifically skeletal, cardiac, and/or trachea-esophageal, than ARM-Net patients. Other patient characteristics were similar. Treatments clearly differed between the groups. European surgeons favoured the PSARP approach for both less complex and more complex ARM types, where Australian surgeons opted more often for cutback surgery in less complex, and laparoscopic assistance in more complex types. Complications were differently distributed, with less complications after LAARP and more after PSARP at RCH, compared to ARM-Net. While RCH patients more often required a redo, ARM-Net patients more commonly underwent anal dilatations. Anorectal malformation patients in Australia and Europe had minor differences in disease characteristics, and both operative and medical approaches differed. Joint efforts such as the present study emphasize the importance of collaboration to elucidate areas of improvement where surgeons may learn from each other across the world, ultimately improving patient outcomes. TYPE OF STUDY: Original Research. LEVEL OF EVIDENCE: III.
A system for delivering a payload nucleic acid into target cells of a subject and production of a payload (or payloads) encoded by the payload nucleic acid in the cells. The system includes a Bifidobacterium sp. bacterium comprising a plasmid and a transporter nucleic acid, the transporter nucleic acid configured for expression in the bacterium. The transporter nucleic acid encodes a transporter polypeptide comprising, in an amino-terminal to carboxy-terminal order, a bacterial secretion signal peptide, a DNA-binding domain to bind the plasmid, and a cell penetrating peptide. The transporter polypeptide complexes with the plasmid and transports the plasmid from the bacterium into the target cells. The plasmid encodes one or more payloads (protein and/or ribonucleic acid) for production in the target cells. The target cells may be colonic cells. When the payload(s) include an antigen, the system may be a DNA vaccine.